Ligand Pharmaceuticals Incorporated (LGND) Q4 2012 Earnings Results

Ligand Pharmaceuticals Reports EPS of $0.14, Stock Up 1.02%

Ligand Pharmaceuticals reported an EPS of $0.14, which was in line with expectations, though no revenue figures were disclosed. The stock reacted positively, rising by 1.02%. The lack of guidance may leave investors uncertain about future performance, but the steady EPS suggests stability in the company's current operations.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.14	N/A	+0.00%

Management

Management commentary

Tone: Neutral

Management maintained a neutral tone during the call, emphasizing ongoing strategic efforts. They did not provide any forward guidance.

Management did not provide specific guidance for the upcoming quarters.

The company remains focused on its strategic initiatives.

Ligand Pharmaceuticals Reports EPS of $0.14, Stock Up 1.02%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Reports EPS of $0.14, Stock Up 1.02%

Key numbers

Management commentary